BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 14584080)

  • 1. Reduced folate carrier protein expression in osteosarcoma: implications for the prediction of tumor chemosensitivity.
    Ifergan I; Meller I; Issakov J; Assaraf YG
    Cancer; 2003 Nov; 98(9):1958-66. PubMed ID: 14584080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of methotrexate resistance in osteosarcoma.
    Guo W; Healey JH; Meyers PA; Ladanyi M; Huvos AG; Bertino JR; Gorlick R
    Clin Cancer Res; 1999 Mar; 5(3):621-7. PubMed ID: 10100715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia.
    Kaufman Y; Drori S; Cole PD; Kamen BA; Sirota J; Ifergan I; Arush MW; Elhasid R; Sahar D; Kaspers GJ; Jansen G; Matherly LH; Rechavi G; Toren A; Assaraf YG
    Cancer; 2004 Feb; 100(4):773-82. PubMed ID: 14770434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression.
    Patiño-García A; Zalacaín M; Marrodán L; San-Julián M; Sierrasesúmaga L
    J Pediatr; 2009 May; 154(5):688-93. PubMed ID: 19159907
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequence alterations in the reduced folate carrier are observed in osteosarcoma tumor samples.
    Yang R; Sowers R; Mazza B; Healey JH; Huvos A; Grier H; Bernstein M; Beardsley GP; Krailo MD; Devidas M; Bertino JR; Meyers PA; Gorlick R
    Clin Cancer Res; 2003 Feb; 9(2):837-44. PubMed ID: 12576457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and epigenetic alterations of the reduced folate carrier in untreated diffuse large B-cell lymphoma.
    Kastrup IB; Worm J; Ralfkiaer E; Hokland P; Guldberg P; Grønbaek K
    Eur J Haematol; 2008 Jan; 80(1):61-6. PubMed ID: 18028428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The folate receptor alpha is frequently overexpressed in osteosarcoma samples and plays a role in the uptake of the physiologic substrate 5-methyltetrahydrofolate.
    Yang R; Kolb EA; Qin J; Chou A; Sowers R; Hoang B; Healey JH; Huvos AG; Meyers PA; Gorlick R
    Clin Cancer Res; 2007 May; 13(9):2557-67. PubMed ID: 17473184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of P-glycoprotein, HER-2/ErbB-2, p53, and Bcl-2 in primary tumor and metachronous lung metastases in patients with high-grade osteosarcoma.
    Ferrari S; Bertoni F; Zanella L; Setola E; Bacchini P; Alberghini M; Versari M; Bacci G
    Cancer; 2004 May; 100(9):1936-42. PubMed ID: 15112275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated physiologic tumor pressure promotes proliferation and chemosensitivity in human osteosarcoma.
    Nathan SS; DiResta GR; Casas-Ganem JE; Hoang BH; Sowers R; Yang R; Huvos AG; Gorlick R; Healey JH
    Clin Cancer Res; 2005 Mar; 11(6):2389-97. PubMed ID: 15788690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis.
    Drozdzik M; Rudas T; Pawlik A; Gornik W; Kurzawski M; Herczynska M
    Pharmacogenomics J; 2007 Dec; 7(6):404-7. PubMed ID: 17325736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas.
    Ferreri AJ; Dell'Oro S; Capello D; Ponzoni M; Iuzzolino P; Rossi D; Pasini F; Ambrosetti A; Orvieto E; Ferrarese F; Arrigoni G; Foppoli M; Reni M; Gaidano G
    Br J Haematol; 2004 Sep; 126(5):657-64. PubMed ID: 15327516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic imbalances associated with methotrexate resistance in human osteosarcoma cell lines detected by comparative genomic hybridization-based techniques.
    Hattinger CM; Reverter-Branchat G; Remondini D; Castellani GC; Benini S; Pasello M; Manara MC; Scotlandi K; Picci P; Serra M
    Eur J Cell Biol; 2003 Sep; 82(9):483-93. PubMed ID: 14582536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. P-glycoprotein expression in osteosarcoma: a basis for risk-adapted adjuvant chemotherapy.
    Baldini N; Scotlandi K; Serra M; Picci P; Bacci G; Sottili S; Campanacci M
    J Orthop Res; 1999 Sep; 17(5):629-32. PubMed ID: 10569469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidrug resistance-1 gene expression does not increase during tumor progression in the MGH-OGS murine osteosarcoma tumor model.
    Trammell RA; Johnson CB; Barker JR; Bell RS; Allan DG
    J Orthop Res; 2000 May; 18(3):449-55. PubMed ID: 10937633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Contrasting effects of oncogene expression on two carrier-mediated systems internalizing folate compounds in Fisher rat 3T3 cells.
    Kühnel JM; Chiao JH; Sirotnak FM
    J Cell Physiol; 2000 Sep; 184(3):364-72. PubMed ID: 10911368
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma.
    Mintz MB; Sowers R; Brown KM; Hilmer SC; Mazza B; Huvos AG; Meyers PA; Lafleur B; McDonough WS; Henry MM; Ramsey KE; Antonescu CR; Chen W; Healey JH; Daluski A; Berens ME; Macdonald TJ; Gorlick R; Stephan DA
    Cancer Res; 2005 Mar; 65(5):1748-54. PubMed ID: 15753370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the multidrug resistance gene in osteosarcoma: a pilot study.
    Wunder JS; Bell RS; Wold L; Andrulis IL
    J Orthop Res; 1993 May; 11(3):396-403. PubMed ID: 8100852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. No correlation between methotrexate serum level and histologic response in the pre-operative treatment of extremity osteosarcoma.
    Bacci G; Loro L; Longhi A; Bertoni F; Bacchini P; Versari M; Picci P; Serra M
    Anticancer Drugs; 2006 Apr; 17(4):411-5. PubMed ID: 16549998
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methotrexate levels and outcome in osteosarcoma.
    Zelcer S; Kellick M; Wexler LH; Shi W; Sankaran M; Lo S; Healey J; Huvos AG; Meyers PA; Gorlick R
    Pediatr Blood Cancer; 2005 Jun; 44(7):638-42. PubMed ID: 15704189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution.
    Bacci G; Longhi A; Versari M; Mercuri M; Briccoli A; Picci P
    Cancer; 2006 Mar; 106(5):1154-61. PubMed ID: 16421923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.